FLT3 and acute myeloid leukemia: For example, Tarlock et al. (2019) reported that FLT3/ITD-mutated AML patients with co-occurring NU98-NSD1 fusions, which are more prevalent among the pediatric population, had inferior outcomes compared to other FLT3/ITD-mutated patients, even when treated with a combination of intensive chemotherapy and sorafenib, followed by hematopoietic stem cell transplantation (Jaju et al., 2001).